Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.16.2 (PCP)
 3,761 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Flecainide, a new antiarrhythmic drug (group 1 according to the classification after Vaughan Williams), is used in the treatment of atrial and ventricular arrhythmias. Cardiac patients are compromised by arrhythmia during operative procedure. The haemodynamic effects of 1 mg/kg b.w. flecainide compared to a placebo solution were studied randomised in 20 patients undergoing coronary artery surgery (before cannulation of the large vessels). Mean arterial pressure, PAP, PCP, PRA and TPR remained unchanged, whereas heart rate (-12%), cardiac index (-17%) and dp/dtmax (-35%) decreased significantly. Total systemic resistance increased by 14%. The results show that it is possible to use flecainide during coronary artery surgery. In patients with reduced myocardial function it should be injected carefully and a decreased dose is recommended with regard to deterioration of left ventricular contractility.
 ...
PMID:[Hemodynamic effects of the anti-arrhythmia agent flecainide (Tambocor) in coronary surgery patients]. 311 31

Early catheterisation was performed in 27 patients with an acute inferior myocardial infarction less than 3 days old complicated by signs of low output with right ventricular dysfunction. All patients had hemodynamic criteria of adiastole (PCP = 14.9 +/- 31 mmHg and LVEDP = 14.1 +/- 4.7 mmHg) with low cardiac output (CI = 1.41 +/- 0.32 l/min/m2). An atropine resistant bradycardia was characteristic (HR = 65 +/- 17.2/min) due to advanced or complete AV block (11 cases), sinoatrial block (3 cases, one with right atrial standstill) or sinus/parasinus rhythm (13 cases) inappropriate to the severity of their hemodynamic state. Although the prognosis based on the discriminating linear function FI = -0.427 + 0.00121 LVW - 0.00125 TPR was initially poor and predicted the death of 21 out of the 27 patients at one month, the outcome was usually favourable and only 8 patients died during the first month. Fifteen patients were treated by temporary endocavitary RV pacing. As the heart rate was increased from 53.8 +/- 11.2 to 92.4 +/- 4.9/min, the CI rose from 1.35 +/- 0.26 to 1.85 +/- 0.46 l/min/m2 (p less than 0.001) with a fall in SI from 26.7 +/- 8.3 to 20.1 +/- 5.6 ml/beat/m2 (p less than 0.005). The results were even further improved in 3 cases by sequential A-V pacing. The observed hemodynamic improvement continued during the period of pacing providing volumic expansion maintained LVEDP above 10 mmHg.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[The value of temporary electrosystolic pacing for treating low output in posterior necrosis with adiastole]. 641 96